Fine-tuning Nanotech to Target Cancer - Technology Review
Fine-tuning Nanotech to Target Cancer
Programmable nanoparticles have shown promise in early cancer trials, and may finally fulfill the promise of nanomedicine.
- THURSDAY, MAY 3, 2012
- BY SUSAN YOUNG

Programmable particle: Bind's drug-delivery nanoparticle (artist's rendering).
Model & image by Digizyme, Inc.
The results of the human trials are startling. Even at a lower-than-usual dose, multiple lung metastases shrank or even disappeared after one patient received only two-hour-long intravenous infusions of an experimental cancer drug. Another patient saw her cervical tumor reduce by nearly 60 percent after six months of treatment. Though the drug trial—by Bind Biosciences in Cambridge, Massachusetts—of an experimental nanotechnology-based technique was designed simply to show whether the technology is safe, the encouraging results revive hopes that nanomedicine could realize its elusive promise.


COCACOLA2 520X245 PHOTO



